Development of antiviral agents for enteroviruses
Development of antiviral agents for enteroviruses
复制标题
DOI：
10.1093/jac/dkn424
复制
发表时间：
2008-12-01
影响因子：
5.2
通讯作者：
Shih, Shin-Ru
中科院分区：
文献类型：
--
作者：
Chen, Tzu-Chun;Weng, Kuo-Feng;Shih, Shin-Ru
肠道病毒（EV）是常见的人类病原体，其与身体的许多器官系统中的许多疾病症状相关。虽然EV感染通常引起轻度或无症状的疾病，但其中一些与严重疾病如CNS并发症有关。目前大多数病毒感染缺乏有效的疫苗，也没有可用的抗病毒药物用于治疗EV，这突出了开发抗病毒药物的紧迫性和重要性。病毒生命周期中的几个关键步骤是阻断病毒复制的潜在靶点。本文综述了近年来基于阻断病毒附着、病毒翻译、多蛋白加工和RNA复制的各种分子靶点的EV抗病毒研究进展。
Enteroviruses (EVs) are common human pathogens that are associated with numerous disease symptoms in many organ systems of the body. Although EV infections commonly cause mild or non-symptomatic illness, some of them are associated with severe diseases such as CNS complications. The current absence of effective vaccines for most viral infection and no available antiviral drugs for the treatment of EVs highlight the urgency and significance of developing antiviral agents. Several key steps in the viral life cycle are potential targets for blocking viral replication. This article reviews recent studies of antiviral developments for EVs based on various molecular targets that interrupt viral attachment, viral translation, polyprotein processing and RNA replication.